



WKN: A2GS5D ISIN: DE000A2GS5D8 Land: Deutschland

Nachricht vom 15.12.2021 | 13:45

## Dermapharm Holding SE: Acquisition of C<sup>3</sup> Cannabinoid Compound Company GmbH

Dermapharm Holding SE / Key word(s): Takeover

Dermapharm Holding SE: Acquisition of C<sup>3</sup> Cannabinoid Compound Company GmbH

15-Dec-2021 / 13:45 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

---

**Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) No. 596/2014 on market abuse, as amended (Market Abuse Regulation - MAR)**

### *Dermapharm Holding SE: Acquisition of C<sup>3</sup> Cannabinoid Compound Company GmbH*

Grünwald, December 15, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), through Dermapharm AG, today entered into an agreement with Canopy Growth Germany GmbH, based in St. Leon-Rot, Germany, to acquire C<sup>3</sup> Cannabinoid Compound GmbH, based in Neumarkt, Germany, and its subsidiaries Spectrum Therapeutics GmbH, based in Neumarkt, Germany, THC Pharm GmbH The Health Concept, based in Frankfurt, Germany, and Spectrum Therapeutics Austria GmbH, based in Vienna, Austria. Upon completion of the transaction, Dermapharm AG will acquire 100.00 percent of the shares in the company, which specializes in the development, production and marketing of natural and synthetic active pharmaceutical ingredients based on cannabinoids. The purchase price is in the order of EUR 80 million plus possible performance-based limited purchase price components.

The closing of the transaction is subject to the approval of the antitrust authorities. The Management Board expects the transaction to be completed by the end of January 2022.

>End of the Ad hoc announcement<

### Contact

Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 - 64186-233

Fax: +49 (0)89 - 64186-165

E-Mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)

---

15-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at [www.dgap.de](http://www.dgap.de)

---

Language: English

Company: Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany

Phone: +49 (0)89 64 86-0

E-mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)

Internet: [ir.dermapharm.de](http://ir.dermapharm.de)

ISIN: DE000A2GS5D8

WKN: A2GS5D

Indices: SDAX

Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in

Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

EQS News ID: 1258267

DGAP News Service

End of Announcement